Ectopically expressed eukaryotic translation initiation factor 4E (eIF4E) stimulates cell proliferation, suppresses apoptosis in growth factor restricted cells, and induces malignant transformation in primary rodent ®broblasts when coexpressed with protooncogene myc. We report here that eIF4E rescued rat embryo ®broblasts ectopically expressing c-Myc ( signi®cantly increased chemosensitivity; either soluble antisense cyclin D1 oligomers or transfection with a dominant negative cyclin D1 mutant that prevents translocation of cyclin D-dependent kinases to the nucleus, signi®cantly blunted the antiapoptotic eect of eIF4E. These data directly link eIF4E rescue from cytostatic drugs to cyclin D1. Since overexpression of eIF4E and cyclin D1 is observed in many aggressive forms of chemoresistant cancers, these ®ndings provide insight into possible mechanisms responsible for this biological behavior.
Introduction
Many cell cycle promoters, such as Ras and Myc, activate both proliferative and apoptotic pathways (Canman and Kastan, 1995; Green et al., 1996; Lungberg and Weinberg, 1999) . Rescue of cycling cells by growth factors, at least in part, occurs through the PI3/Akt kinase pathway, which can operate independently of translational control (Datta et al., 1997; del Peso et al., 1997; Franke et al., 1997; Gonzalez-Garcia et al., 1997; Kennedy et al., 1997) . We have reported a growth factor activated anti-apoptotic mechanism which operates through translation initiation factor 4E (eIF4E) (Polunovsky et al., 1996) . A 24 kD polypeptide, eIF4E interacts with the cap structure (m 7 GpppX, where X is any nucleotide) of eukaryotic mRNA directing the translation machinery to the 5' end of most mRNA (reviewed in Sonenberg, 1996; Sonenberg and Gingras, 1998) . During translation initiation, eIF4E interacts with eIF4G, a translation factor which serves as a docking protein for the binding of other initiation factors and for formation of the translation pre-initiation complex. This function of eIF4E is negatively regulated by members of a family of eIF4E-binding proteins (4E-BPs), also called PHAS Pause et al., 1994) , which competes with eIF4G for a binding domain on eIF4E. In most cell systems, eIF4E is rate limiting for translation initiation and a major target for translational control by extracellular stimuli. Consistent with this function, eIF4E is required for cell cycle transit as well as viability, and when overexpressed, collaborates with Myc in transformation of primary rodent ®broblasts (reviewed in Sonenberg and Gingras, 1998) . However, the mechanism by which eIF4E blocks apoptosis is unknown. Our objective in the present report was to determine whether eIF4E rescues Myc transformed cells from apoptosis when cell cycle transit is perturbed by cytostatic drugs, and to identify a candidate mRNA whose protein product mediates that rescue.
While eIF4E increases all cap-dependent mRNA utilization, it upregulates the initiation or nuclear export of certain transcripts preferentially (reviewed in Sonenberg, 1996) . Among those cap-dependent transcripts subject to strong translational control, prior studies have identi®ed two that are integral to cell cycle transit and therefore encode proteins that might rescue cycling cells from oncogene activated apoptosis. These proteins are ornithine decarboxylase (ODC) (Rousseau et al., 1996b; Shantz and Pegg, 1994; Shantz et al., 1996) an enzyme involved in polyamine synthesis, and the G1 progression factor cyclin D1 (Rosenwald et al., , 1995 Rousseau et al., 1996b) . ODC, however, has been shown to be proapoptotic, acting downstream of Myc in mediating apoptosis. Pharmacological inhibition of ODC attenuates Myc-dependent apoptosis while overexpression of ODC induces apoptosis (Packham and Cleveland, 1995) . The eect of cyclin D1 can be pro-or anti-apoptotic depending on the proliferative and dierentiated state of the cell (reviewed in Han et al., 1999) . Enforced expression of cyclin D1 in quiescent, post-mitotic neurons (Kranenburg et al., 1996) , growth restricted ®broblasts (Sofer-Levi and Resnitzky, 1996) , or irradiated ®broblasts (Pardo et al., 1996) stimulates cell cycle entry and leads to apoptosis. However, in cells ectopically expressing strong growth promoters, such as Myc and Ras, high levels of D-cyclins (cyclins D1, D2, and D3) rescue cells from apoptosis induced by dexamethasone (Rhee et al., 1995) or cytotoxic drugs (Warenius et al., 1996) . In addition, inhibition of cyclin D1 sensitizes lung cancer cells to apoptosis when serum survival factors are withdrawn (Driscoll et al., 1999) . Moreover, cyclin D1 may serve a rescue function in retinal development, since photoreceptor cells of cyclin D1 null mice undergo apoptosis during early postnatal life . Based on these considerations, in this report we examine whether eIF4E rescue of ®broblasts from Myc-dependent apoptotic death requires translational activation of cyclin D1.
Results
Ectopic expression of eIF4E rescues fibroblasts constitutively expressing c-Myc from apoptosis Constitutive Myc expression alone upregulated eIF4E levels , and this was signi®-cantly increased by infection with a retrovirus encoding wild-type eIF4E (Figure 1a) . Cell extracts were reacted with an agarose immobilized 7-methyl GTP cap analog to examine whether ectopic eIF4E expression in REF/ Myc changed the binding of eIF4E to one of its partners in the pre-initiation complex, eIF4GI, or to its competitive inhibitor, translation repressor 4E-BP1. Ectopic expression of eIF4E in REF/Myc did not signi®cantly alter these binding patterns (Figure 1b) . Furthermore, the electrophoretic mobility of the 4E-BP1 co-precipitated with eIF4E was similar for REF/ Myc and REF/Myc/4E (Figure 1b, bottom) . These ®ndings indicate that in REF/Myc/4E, the level of eIF4E protein was increased without perturbing its distribution between 4E-BP1 and eIF4G.
Consistent with published reports (Harrington et al., 1994) , addition of cell cycle speci®c cytostatic agents to were lysed and whole cell extracts (40 mg of total protein) were subjected to SDS ± PAGE (12%), blotted onto nitrocellulose, and probed with anti-eIF4E antibody before visualization by enhanced chemiluminescence. Actin is shown as a control for protein loading. (b) Partitioning of eIF4E between translation initiation factor eIF4GI and translational repressor 4E-BP1. Cell lysates were reacted with solid phase cap analogue (25 ml of 7-methyl-GTP agarose beads) to capture eIF4E and its binding partners. Shown are immunoblots for cap-bound eIF4E and the amounts of co-precipitated eIF4GI and 4E-BP1 in REF/Myc and REF/ Myc/4E. Shown below each blot are densitometry values in arbitrary units. (c) Drug-induced apoptosis. Experimental conditions: each cell line was incubated with the indicated cytostatic agent in DMEM containing 10% FCS for 24 h and analysed for hypodiploid DNA content by¯ow cytometry. Cont=complete medium. The following cytostatic agents were added to complete medium: Lov=lovastatin, 5 mM; Mim=mimosine, 60 mg/ml; Thym=thymidine, 4 mM; HU=hydroxyurea, 2 mM; Aph=aphidicolin, 1.5 mg/ml; Cam=camp-tothecin, 75 nm; Colc=colcemide, 50 ng/ml. Data are the averages from a minimum of three separate experiments+s.d. REF/Myc increased apoptotic frequency four to ninefold compared to parental REF (Figure 1c ) . The degree of apoptosis was greatest in cells exposed to G1 active cytostatic agents and progressively decreased in magnitude with cytostatic agents active in the remainder of the cell cycle. In contrast, REF/Myc coexpressing eIF4E were resistant to cytostatic agent -induced cell death. In most cases, overexpression of eIF4E nearly eliminated apoptosis. These data extend our prior ®ndings that eIF4E suppresses apoptosis in response to serum restriction (Polunovsky et al., 1996) , and indicate that eIF4E robustly suppresses apoptosis in response to both genotoxic and non-genotoxic cytostatic drugs.
Steady state levels of cyclin D1 are increased by ectopic expression of eIF4E
To explore whether D cyclins could be implicated in the mechanism of eIF4E rescue from apoptosis, we examined if ectopic expression of eIF4E in REF/Myc increased steady state levels of this family of G1 progression factors. Cyclin D1 is reported to be the predominant D cyclin in ®broblasts, while cyclins D2 and D3 are mainly expressed in cells of lymphocytic lineage Ando et al., 1993; Tam et al., 1994 (Figure 2a ). Immunoblot analysis corroborated these results identifying increased levels of cyclin D1 under all conditions where rescue from apoptosis was observed (Figure 2b) . This was the case even in the presence of cytostatic drugs, where cyclin D1 expression in REF/ Myc was barely detectable or below the detection threshold. These data are consistent with cyclin D1 as a candidate mediator of eIF4E rescue from apoptosis.
Ectopic expression of eIF4E increases de novo synthesis of cyclin D1 and stimulates cyclin D-dependent kinase activity Overexpression of eIF4E is known to lead to a selective increase in the cyclin D1 mRNA nucleocytoplasmic transport (Rousseau et al., 1996b) . Direct quantitation of cyclin D1 synthesis by pulse-labeling with . These data demonstrate that the increased levels of cyclin D1 resulting from ectopic expression of eIF4E is accompanied by increased cyclin D-dependent kinase activity.
Cyclin D1 levels parallel resistance to apoptosis in REF/Myc ectopically expressing eIF4E
In general, there is a direct relationship between the level of eIF4E and the level of cyclin D1 in ®broblasts ectopically expressing eIF4E (Rousseau et al., 1996b) . However, in the course of characterizing many independent REF/Myc/4E clones (n=17), we discovered one clone (REF/Myc/4E #4) where the eIF4E level was relatively low and the cyclin D1 level was relatively high. We took advantage of this anomaly to determine if the antiapoptotic function of eIF4E could be dissociated from the level of cyclin D1, and examined apoptosis as a function of eIF4E and cyclin (Figure 5b ). Thus, similar to eIF4E, ectopic cyclin D1 suppressed Myc-dependent apoptosis in response to a broad range of cytostatic drugs.
Partial loss-of-cyclin D1 function sensitizes REF/Myc/4E to apoptosis from lovastatin
We ®rst examined whether cyclin D1 was required for eIF4E-mediated rescue of REF/Myc by reducing cyclin D1 levels with antisense oligomers. The use of a 20-mer phosphorothioate modi®ed antisense oligodeoxynucleotide (ASO) directed against the AUG start codon of the cyclin D1 mRNA has been shown to eectively reduce the total level of cyclin D1 (Hung et al., 1996) . A 6 h incubation of REF/Myc/4E with ASO reduced total cyclin D1 levels by approximately 75% when compared to treatment with a 20-mer scrambled oligodeoxynucleotide control (SCR), although scrambled oligomer did decrease cyclin D1 levels somewhat below control values (Figure 6a ). REF/ Myc/4E were incubated with 50 mM ASO, 5 mM lovastatin, or both for 30 h. Parallel experiments were performed using SCR. Apoptosis was quanti®ed using the morphologic criteria of nuclear condensation and fragmentation, and cytoplasmic blebbing. Treatment of REF/Myc/4E with ASO and lovastatin led to morphological changes characteristic of apoptosis ( Figure 6b ) and signi®cantly increased the apoptotic frequency ( Figure 6c) .
A second loss-of-function approach was employed to corroborate the ®ndings with antisense oligomers, particularly in view of the decreased cyclin D1 levels and increased death rate observed with SCR. For these experiments, we chose to transiently transfect REF/ Myc/4E with a dominant negative cyclin D1 mutant in which threonine-156 is replaced with alanine (T156A). This mutant cyclin D1 assembles with its Cdk partner, but fails to localize to the nucleus and therefore forms catalytically inactive complexes (Diehl and Sherr, 1997) . Transient expression of this mutant in REF/ Myc/4E sensitized cells to lovastatin (5 mM), resulting in an apoptotic frequency of 42%. In contrast, cells transfected with empty vector remained viable ( Figure  7 ). These ®ndings indicated that nuclear localization of cyclin D1-dependent kinases was required for eIF4E-mediated rescue from cytostatic drugs.
Discussion
Cell cycle transit requires the function of c-Myc, a transcriptional regulatory phosphoprotein that has also been implicated in the activation of apoptosis (reviewed in Dang, 1999; Harrington et al., 1994; Thompson, 1998) . As a result, cells with ectopic expression of c-Myc have been used as model systems to study the interplay between proliferation and apoptosis. Such cells are highly susceptible to apoptosis following serum deprivation or incubation with cytostatic agents (Evan et al., 1992; Harrington et al., 1994) . We have previously determined that the mRNA cap binding protein, eIF4E, blocks apoptosis in growth factor restricted ®broblasts expressing physiologically regulated or deregulated c-Myc (Polunovsky et al., 1996) . Here we report that rescue from cell cycle-active cytostatic drugs by ectopic eIF4E expression results from increased levels of cyclin D1. In clones of REF/ Myc ectopically expressing eIF4E, cell viability paral- leled the levels of cyclin D1, rather than eIF4E. Ectopic cyclin D1 conferred REF/Myc with resistance to cytostatic drug-induced apoptosis, while decreasing cyclin D1 protein levels or inhibiting its ability to localize active kinase complexes to the nucleus sensitized REF/Myc/4E to apoptosis. These data identify the role of cyclin D1 as a downstream eector in the mechanism of eIF4E-mediated rescue from apoptosis.
Translational activation of cyclin D by ectopic eIF4E has been shown to involve increased transport of transcripts from the nucleus to the cytoplasm (Rosenwald et al., 1995; Rousseau et al., 1996b) . This augmented synthesis of cyclin D1 by eIF4E could have been due to increased levels of eIF4E protein, an increase in its state of activation, or both. Here we show that ectopic expression of eIF4E in ®broblasts with deregulated Myc led to a substantial increase in the rate of cyclin D1 synthesis. This resulted in a signi®cantly increased steady state cyclin D1 level in both the nucleus and cytoplasm. This increase was observed in all phases of the cell cycle, and associated with activation of the cyclin D-dependent kinases, Cdk4 and Cdk6.
Important events regulating eIF4E occur at the transcriptional and post-translational levels (reviewed by Raught and Gingras, 1999) . While it is clear that deregulated expression of Myc alone can lead to upregulation of eIF4E levels, through transcriptional activation , this increased eIF4E expression is insucient to block apoptosis. In addition to transcriptional activation, two key kinase cascades have been shown to modulate eIF4E function. One involves MAP and Mnk kinases (Pyronnet et al., 1999; Waskiewicz et al., 1999) leading to phosphorylation of serine 209 on eIF4E. This pathway is felt to ®ne-tune the anity of eIF4E for the 7-methyl guanosine cap of mRNA. The major regulatory pathway involves PI3, Akt, and FRAP kinases which phosphorylate a family of translational repressors, the 4E-BPs . When hypophosphorylated, the 4E-BPs compete with translation initiation factor eIF4G for a common binding site on eIF4E, and thus repress translation initiation. When hyperphosphorylated, the anity of the 4E-BPs for eIF4E decreases, permitting eIF4E to bind its translation partner eIF4G, a key step in assembly of an intact translation preinitiation complex. Our data demonstrate that ectopic expression of eIF4E in ®broblasts with deregulated Myc did not signi®cantly alter the association of eIF4E with 4E-BP1 or eIF4G. These results therefore suggest that rescue of ®broblasts with deregulated Myc by eIF4E requires that a critical level of eIF4E protein be attained, that is sucient to augment cyclin D1 beyond its rescue threshold.
Our ®ndings directly demonstrate that cyclin D1 can confer chemoresistance to cells with deregulated Myc expression, but the downstream reactions underlying this resistance are unknown. One possibility is that cyclin D1 functions by activating Cdk4 or Cdk6 or sequestering Cdk inhibitors (Poon et al., 1995) , p21 and p27, which have been strongly linked to apoptosis when expressed at the wrong time in the cell cycle (Duttaroy et al., 1997; Katayose et al., 1997; Wang et al., 1997) . The most widely recognized function of cyclin D-dependent kinases is phosphorylation of pRb which disrupts association of pRb with E2F family proteins (Sherr and Roberts, 1999) . One member of the E2F family, E2F-1, has been implicated in activation of apoptosis which is negatively regulated by pRb (Phillips et al., 1999; Fan and Steer, 1999) . However, hypophosphorylated pRb is also able to induce apoptosis by stabilizing p53 (Hsieh et al., 1999) , a function which might be abrogated by cyclin D-dependent phosphorylation of pRb. Alternatively, the anti-apoptotic function of cyclin D1 may be independent of its ability to modulate kinase activity. A novel role for cyclin D1 recently described is activation of the estrogen receptor leading to gene expression, which occurs through a direct interaction of cyclin D1 with the estrogen receptor in a cdk independent manner (Neuman et al., 1997; Zwijsen et al., 1997) . Similarly, a non-cdk dependent transcriptional regulatory function for cyclin D1 has been documented In parallel experiments, SCR was used. Apoptosis was quanti®ed by counting apoptotic cells following acridine orange staining. A minimum of 500 cells were counted for each data point and four independent experiments were performed for transcription factor DMP1, which inhibits cell cycle transit. Binding of cyclin D1 to DMP1 prevents its association with DNA and permits cell cycle transit to proceed (Inoue and Sherr, 1998) . This raises the possibility that cyclin D1 might rescue cells from apoptosis by transcriptional inactivation of a survival gene or transcriptional activation of a death gene in a Cdk-independent manner. While our data does not de®nitively resolve this issue, our results with the dominant negative cyclin D1 construct implicate nuclear localization of cyclin D-dependent kinases in the mechanism.
D cyclins are found to be pro-apoptotic in some studies, yet anti-apoptotic in others, including the present report. A number of investigators analysing tissue from human cancers (de Jong et al., 1998; Kotelnikov et al., 1997) , Alzheimers patients (Busser et al., 1998) , breast (Mommers et al., 1998) , adrenalectomized rats (Postigo et al., 1998) and stroke (Giardina et al., 1998; Guegan et al., 1997; Li et al., 1997; Liu et al., 1996; Timsit et al., 1999) all ®nd D cyclins increased in those regions where cell death is observed.
Whether this represents a lethal function of cyclin D, or an abortive attempt at rescue cannot be determined from this correlative work. A compelling link between D cyclins and induction of apoptosis is provided by direct gain of cyclin D1 function studies in cell systems where overexpressed cyclin D promoted ectopic cell cycle transit (Hiyama and Reeves, 1999; Kranenburg et al., 1996; Sofer-Levi and Resnitzky, 1996) . Mitigating this are the data in this report along with other investigations utilizing direct gain-and-loss of D cyclin function in lymphoid cells (Rhee et al., 1995; Warenius et al., 1996) , cells from pancreatic carcinoma (Kornmann et al., 1997) and lung cancer cells (Driscoll et al., 1999) . Moreover, recent ®ndings demonstrate that transcriptional upregulation of endogenous cyclin D1 by activating its promoter, inhibits apoptosis (Albanese et al., 1999) , whereas antisense cyclin D1 induces apoptosis and decreases tumor size in human squamous carcinomas (Sauter et al., 1999) . These studies show that many types of cells driven to ectopically transit the cell cycle by growth promoters other than D-type cyclins can be rescued by D cyclins from serum deprivation, lethal irradiation or cytostatic drugs. Of particular note are data which show that c-Myc and cyclin D3 individually sensitize lymphoid cells to dexamethasone-induced apoptosis, whereas co-expression of c-Myc and cyclin D3 rescues cells (Rhee et al., 1995) ; results in close accord with our ®ndings. In concert with these in vitro experiments, developmental studies in cyclin D1 null mice suggest a critical role for cyclin D1 in preserving viability of retinal photoreceptor cells , and in suppression of apoptosis in cyclin D1 knockout ®broblasts (Albanese et al., 1999) .
What emerges from this body of evidence is that cyclin D1 ± similar to activated Ras ± apparently stimulates both proapoptotic and antiapoptotic pathways. The net eect of cyclin D1 on cell viability appears to be in¯uenced by several factors which potentiate or dampen these contradictory eector pathways. These include proliferative state, the integrity of cell cycle check points, and the nature of the proapoptotic stimulus (survival factor withdrawal, cytostatic drugs, radiation, apoptotic agonists). Precise mechanism awaits identi®cation of the biochemical reactions connecting D cyclins to the apoptotic apparatus.
Our results have important implications for therapy of human malignancies. Constitutive upregulation of eIF4E leads to suppression of oncogene dependent apoptosis and confers transformed cells with resistance to cytostatic agents. eIF4E, like Ras, cooperates with Myc and E1A in cell transformation in vitro and in vivo (Lazaris-Karatzas et al., 1992) . Overexpressed eIF4E has been detected in breast cancer tissue and other malignant cell lines (reviewed in De Benedetti and Harris, 1999) indicating a link to carcinogenesis. Upregulation of cyclin D1 expression is associated with many forms of premalignant and malignant lesions, including human parathyroid adenomas, B cell lymphoma, squamous carcinomas of the esophagus, head, and neck; and cancers in breast, colon, lung, bladder, and liver (reviewed in Hunter and Pines, 1994) . Where studied, expression of cyclin D1 has been linked to a poor response to therapy and decreased disease-free survival periods (Gansauge et al., 1997; Kornmann et al., 1998; Schuuring et al., 1992) . Recent data indicate that eIF4E is increased in colon adenomas and carcinomas, and this increase is accompanied in most but not all cases by elevation in cyclin D1 levels (Rosenwald et al., 1999) . These ®ndings support our observation that increased expression of eIF4E does not necessarily upregulate cyclin D1, and also suggest that cyclin D1 mediates some but not all eIF4E eector pathways leading to tumor formation. Thus, in addition to the role of cyclin D1 in regulating cell cycle transit, its ability to block cell death in response to both genotoxic and non-genotoxic cytostatic agents may be a previously unrecognized mechanism responsible for the resistance of some cancers to therapy.
Materials and methods

Cell lines, cell culture and transfections
Cell lines were derived from rat embryonic ®broblasts (REF Diehl and Sherr, 1997 ) and a puromycin selectable marker using DNA-calcium phosphate-mediated gene transfer. Selection was achieved in`complete medium' [Dulbecco's modi®ed Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS), 4.5 g/L glucose, 100 U/ml penicillin, 100 U/ml streptomycin, and 250 ng/ml amphotericin B] containing puromycin (2 mg/ml). Transient transfection of REF/Myc/ 4E with apFLEX1 encoding Flag-tagged murine dominant negative cyclin D1 (T156A) or Flag alone was performed using Superfect (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's directions.
Cell cycle active cytostatic drugs
Cells were incubated in complete medium for 24 h with the indicated agent. The drug concentration selected re¯ects the dose required to synchronize 75% of REF (i.e. an ED 75 for cytostatic eect) as determined by¯ow cytometry. The G1 active agents used were 5 mM lovastatin and 60 mg/ml mimosine. Lovastatin solution was prepared by the extraction and activation of the lactone from the tablet drug as previously described (Tan et al., 1999) . S phase active agents included 2 mM hydroxyurea, 1.5 mg/ml aphidicolin, and 4 mM thymidine. The G2 and M phase active agents used were 75 nM camptothecin and 50 ng/ml colcemide, respectively. All cytostatic agents were purchased from Sigma chemicals (St. Louis, MO, USA) with the exception of lovastatin which was obtained from Merck, Sharpe, and Dohme (Rathway, NJ, USA).
Cell cycle and apoptosis analysis DNA content was quanti®ed using¯ow cytometry to assess cell synchronization and apoptosis (Becton-Dickinson FACS Star Plus and FACS Caliber, Lincoln Park, NJ, USA). Cells were seeded in 6-well clusters at 1.5610 4 cells/cm 2 . After treatment with a cytostatic agent, detached cells were collected, combined with adherent cells which were released by trypsin, and ®xed with 70% ethanol (1 h, 48C). The ®xed cells were washed with PBS and stained with propidium iodide stain (PBS containing 50 mg/ml propidium iodide, 0.05% Triton X-100, 37 mg/ml EDTA, 2.5 U/ml RNase) for 45 min at 378C. DNA histograms were analysed using Cell Quest software and cells with hypodiploid DNA content were de®ned as apoptotic. For each experimental condition, apoptosis was con®rmed using TUNEL, acridine orange staining, or ultrastructural analysis as previously described (Polunovsky et al., 1993 (Polunovsky et al., , 1994 (Polunovsky et al., , 1996 .
Immunoblot analysis
Detection of eIF4E and c-Myc were performed as previously described . Forty mg of total cellular protein was separated by SDS ± PAGE (12%), blotted onto nitrocellulose, developed with anti-eIF4E (Transduction Laboratories, Lexington, KY, USA; 1 : 500) or anti-c-Myc (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA; 1 : 100) antisera, and the appropriate horse-radish peroxidaseconjugated secondary IgG antibody (Sigma Chemical, St. Louis, MO, USA; 1 : 5000). Blots were visualized by enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The presence of c-Myc in REF/Myc/4E clones was veri®ed to rule out the possibility that any new phenotype observed was due to loss of c-Myc expression. For immunoblot analysis of D cyclins, 40 mg of cytoplasmic extract prepared using a NP-40 lysis buer (Poon et al., 1995) was subjected to SDS ± PAGE (12%) under reducing conditions, and blotted onto nitrocellulose. The blot was proved using primary antibodies against cyclins D1, D2, and D3 (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA; 1 : 200), appropriate horseradish peroxidase labeled secondary antibodies, and visualized by ECL. Densitometric analysis was performed by scanning immunoblots and quantitating protein bands using the software`Molecular Analysis' (BioRad, Richmond, CA, USA). Background readings were subtracted from all values which were expressed in arbitrary OD units. When applicable, the OD was normalized to actin to account for variations in loading among samples.
Co-precipitation of cap-bound eIF4E with eIF4GI or 4E-BP1
To quantitate 4E-BP1 or eIF4GI bound to eIF4E, cells were collected by scraping into buer A (150 mM NaCl, 50 mM Tris pH 7.5, 50 mM NaF, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 50 mM b-glycerophosphate, 10 mM Na pyrophosphate, 0.1 mM Na orthovanadate, 50 nM okadaic acid, 1 mM PMSF, 10 mg/ml pepstatin A, 10 mg/ml leupeptin), and cell membranes were disrupted by three successive freeze ± thaw cycles. The cell extracts were microcentrifuged at 48C for 10 min and the supernatants were retained. Lysates containing 250 mg protein were diluted with buer A to a ®nal volume of 200 ml and mixed with 25 ml of packed 7-methyl-GTP agarose beads (Amersham Pharmacia Biotech) that were pre-equilibrated with buer B (50 mM Tris, pH 7.5, 150 mM NaCl). Each lysate was mixed with beads in a microcentrifuge tube for 1.5 h at 48C under constant gentle agitation, followed by a brief centrifugation to pellet the beads. The pelleted beads with bound material were washed twice with 0.5 ml of buer B and eluted with 50 ml of buer C (25 mM Tris, pH 7.5; 75 mM NaCl; 70 mM 7-methyl-GTP). The 50 ml of elute were separated from the beads, subjected to SDS ± PAGE and transferred to nitrocellulose. Blots were probed ®rst with mouse anti-eIF4E (Transduction Labs, 1 : 500); stripped and probed for 4E-BP1 (rabbit polyclonal antiserum, 1 : 2500) Rousseau et al., 1996a) ; stripped and probed for eIF4GI (rabbit polyclonal antisera, 1 : 4000) (Gradi et al., 1998 Smethionine (20 mCi/ml, 1000 Ci/mmol) in methionine free DMEM supplemented with 10% dialyzed FCS. For analysis of cyclin D1 synthesis, at the indicated times, cells were washed with PBS and lysed. All lysates were immunoprecipitated with 1 mg cyclin D1 antibody (Santa Cruz Biotechnologies, Inc.) and 25 ml of packed protein G-sepharose beads in a total volume of 300 ml. Beads were collected, washed three times with lysis buer and immune complexes were eluted with 35 ml SDS sample buer. Samples were subjected to SDS ± PAGE (12%), the gel was dried and exposed to X-ray ®lm.
Immunostaining for cyclin D1
Cells were rinsed brie¯y, ®xed with 3% paraformaldehyde for 15 min at 48C, rinsed, permeabilized with 1% Triton X-100 for 2 min, rinsed, and blocked with 2% BSA/10% normal horse serum. Mouse anti-cyclin D1, (Santa Cruz Biotechnology) was applied at 1 mg/ml for 2 h, followed by biotinylated horse anti-mouse IgG at 1 : 100 for 45 min. Slides were washed and mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA, USA) for viewing in a Leica Leitz DMR¯uorescence microscope. Photos were taken at equal exposure times to ensure accurate comparisons. Controls were treated with substitution of non-immune mouse serum for primary antibody or omission of primary antibody. Buer for all rinses and incubations was PBS, pH 7.4 unless otherwise stated in the text.
Immunostaining for Flag
Cells were ®xed with 100% methanol at 7208C for 2 h, rinsed with PBS, and incubated for 16 h at 48C with goat anti-Flag antibody (3 mg/ml, Research Diagnostics Inc., Flanders, NJ, USA) or with non-immune serum (goat IgG, 3 mg/ml, PharMingen, San Diego, CA, USA), followed by rinsing and incubation with¯uorescein-conjugated anti-goat IgG antibody (1 : 40, Sigma) for 30 min. All antibodies were diluted in PBS containing 1% bovine serum albumin and 0.5% Triton X-100. All samples were also stained with propidium iodide (50 mg/ml) for 20 min prior to measurement of non-speci®c or Flag-speci®c green emission of uorescein, and red emission of propidium stained DNA using standard optics of the FACS Star Plus¯ow of cytometer and CellQuest.
Reduction of steady state levels of cyclin D1 using antisense oligodeoxynucleotides A 20-mer antisense phosphorothioate oligodeoxynucleotide spanning the AUG translation start codon on human cyclin D1 mRNA (5' GAG-CTG-GTG-TTC-CAT-GGC-TG 3'; Promega, Madison, WI, USA) was used to reduce cyclin D1 protein levels, with the expected decrement veri®ed at 6 h by immunoblot as previously reported (Hung et al., 1996) . A scrambled 20-mer oligodeoxynucelotide was used as a control (5' AGA-TCA-TGA-CGT-TCC-ATT-CG 3') in parallel experiments. Cells were plated into 48-well clusters at 1.5610 4 cells/cm 2 in complete medium overnight, and shifted to complete medium with 5 mM lovastatin, 5 mM oligodeoxynucleotides, or both, for 30 h. This interval was chosen to evaluate the eect of lovastatin for a full 24 h after the veri®ed decrease in cyclin D1 levels, 6 h after ASO addition. Cells were ®xed with 70% ethanol (1 h, 48C) and stained with acridine orange. Apoptotic cells were quantitated morphologically by¯uorescence microscopy using previously established criteria (Polunovsky et al., 1996) . At least 500 cells were counted per well and four independent experiments were performed.
Cyclin D-dependent kinase assays
Kinase activity was determined as described by (Matsushime et al., 1994) , with minor alterations. Cells were suspended in lysis buer containing 0.1% Tween-20 and sonicated. Clari®ed lysates from 1.5610 6 cells were immunoprecipitated with antibodies against cyclin D1, Cdk4, or Cdk6 (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA; 1 mg) for 16 h. Immune complexes were collected using protein Gsepharose beads. Washed beads were added to a kinase assay reaction mix containing pRb substrate (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA; 1 mg/sample) and [g-32 P]ATP for 30 min at 378C. The reaction was quenched by the addition of sample buer. Samples were boiled prior to separation by SDS ± PAGE (10%). Phosphorylation of Rb was visualized by autoradiography.
